Oppenheimer Reiterates Hold Rating for Insys Therapeutics (INSY)
INSY has been the subject of several other research reports. Zacks Investment Research lowered Insys Therapeutics from a hold rating to a sell rating in a research report on Thursday, February 22nd. ValuEngine lowered Insys Therapeutics from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Piper Jaffray Companies lowered Insys Therapeutics from a neutral rating to an underweight rating in a research report on Friday, March 9th. Finally, Cann restated an average rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of Hold and a consensus price target of $9.38.
Insys Therapeutics (INSY) opened at $7.02 on Friday. The company has a market capitalization of $514.68, a PE ratio of -2.23 and a beta of 1.02. Insys Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.02.
Several large investors have recently made changes to their positions in INSY. Dynamic Technology Lab Private Ltd purchased a new position in shares of Insys Therapeutics during the third quarter valued at approximately $119,000. Janney Montgomery Scott LLC purchased a new position in shares of Insys Therapeutics during the third quarter valued at approximately $135,000. Stone Ridge Asset Management LLC purchased a new position in shares of Insys Therapeutics during the fourth quarter valued at approximately $137,000. Voya Investment Management LLC purchased a new position in shares of Insys Therapeutics during the second quarter valued at approximately $149,000. Finally, Royal Bank of Canada boosted its position in shares of Insys Therapeutics by 100.9% during the second quarter. Royal Bank of Canada now owns 13,695 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 6,877 shares during the period. Institutional investors and hedge funds own 24.19% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.